How Saunders was paid
$32.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Brenton L. SaundersChairman of the Board and Chief Executive Officer | $1,600,000 | — | $23,778,578 | $2,799,998 | $4,000,000 | $15,750 | $32,194,326 |
| Sam A. EldessoukyExecutive Vice President and Chief Financial Officer | $777,981 | $250,000 | $2,514,714 | $659,996 | $744,000 | $15,750 | $4,962,441 |
| A. Robert D. BaileyExecutive Vice President and Chief Legal Officer | $767,942 | — | $1,714,561 | $449,998 | $673,200 | $27,250 | $3,632,951 |
| Yehia Hashad, M.D.Executive Vice President of Research & Development and Chief Medical Officer | $726,116 | — | $1,066,839 | $279,996 | $700,800 | $15,750 | $2,789,501 |
| Andrew J. StewartPresident, Global Pharmaceuticals and International Consumer | $629,077 | — | $990,631 | $259,995 | $604,800 | $15,750 | $2,500,253 |
What changed and why
- $32.2MCEO total compensation rose to $32,194,326 in 2025 primarily due to equity modifications and stock award valuations.
- 97%Approximately 97 percent of shareholders voted in favor of executive compensation at the 2025 annual meeting.
- Performance metrics for incentives included organic revenue growth and relative total shareholder return.
- 166%Organic revenue growth PSU awards vested at 166 percent of target based on three-year performance.
- The company maintains robust share ownership guidelines and holding requirements for executive officers.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.